EC approves Alprolix for the treatment of haemophilia

Swedish Orphan Biovitrum AB (Sobi) and Biogen have announced that the European Commission (EC) has approved Alprolix (rFIXFc) for the treatment of haemophilia B and maintained its orphan designation. Alprolix is the only recombinant factor IX Fc Fusion protein therapy for haemophilia B to offer people in the EU prolonged protection against bleeding episodes with fewer prophylactic injections.…

Implantable cardioverter-defibrillators can reduce sudden death in young patients with hypertrophic cardiomyopathy

A multicenter registry has demonstrated that the use of implantable cardioverter-defibrillators (ICDs) to combat sudden cardiac death in high-risk pediatric patients suffering from hypertrophic cardiomyopathy (HCM). The study is being presented Nov. 5 at the 2012 Scientific Sessions of the American Heart Association (AHA) in Los Angeles. While the study found that the rate of…

New research unlocks a mystery of albinism

Newly published research provides the first demonstration of how a genetic mutation associated with a common form of albinism leads to the lack of melanin pigments that characterizes the condition. About 1 in 40,000 people worldwide have type 2 oculocutaneous albinism, which has symptoms of unsually light hair and skin coloration, vision problems, and reduced…